AAV Vector Manufacturing for NHP Toxicology Programs
PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES
AAV Vector Manufacturing for NHP Toxicology Programs
CELL & GENE | RNA | BIOLOGICS
Proven Intelligence in Preclinical Vector Strategy.
Executive Summary
Generating clean, interpretable data from IND-enabling toxicology studies in nonhuman primate (NHP) models begins with the vector. A manufacturing process designed for basic research is insufficient for the rigor of GxP-compliant toxicology. This page details the requirements for producing AAV vectors specifically engineered for NHP safety and biodistribution programs, focusing on the quality attributes that directly influence in vivo outcomes and regulatory acceptance. This work is performed by the core scientific team that has maintained a 100% successful IND submission rate since 2019, prior to the formal launch of Franklin Biolabs in 2024.
Frequently Asked Questions
Why is a standard research-grade AAV vector insufficient for IND-enabling toxicology studies?
A research-grade vector is typically characterized by titer alone. For IND-enabling toxicology studies, regulatory bodies require extensive data on purity (empty/full capsid ratio), aggregation, process-related impurities, and potency. These attributes, managed under a GxP framework, are required for ensuring batch-to-batch consistency and accurately interpreting safety signals in NHP models.
How does AAV vector design influence the outcomes of NHP toxicology programs?
Vector design, including capsid selection and promoter/transgene elements, directly dictates tissue tropism and expression levels. An improperly selected capsid can lead to poor non-target tissue biodistribution or unintended immune responses, confounding toxicology data. The manufacturing process must preserve the integrity of this design to ensure the vector used in NHP studies is representative of the intended clinical product.
What defines an “IND-ready” AAV vector batch for NHP models?
An “IND-ready” AAV vector is one produced with a well-documented, consistent manufacturing process and characterized by a comprehensive analytical package. This includes data on identity, purity, concentration, and potency. The batch is manufactured with the specific demands of in vivo NHP administration in mind, including low endotoxin levels and formulation stability, to support a successful submission.
Defining Vector Quality for In Vivo NHP Applications
The transition from discovery to formal preclinical evaluation requires a significant shift in AAV manufacturing philosophy. For IND-enabling toxicology studies conducted in NHP models, the vector functions as the primary variable under investigation. Its quality attributes directly impact the integrity of the safety and biodistribution data submitted to regulatory agencies.
Key vector characteristics that influence in vivo outcomes include:
-
Empty/Full Capsid Ratio: An excess of empty capsids can contribute to unnecessary immunogenicity without providing therapeutic benefit, potentially complicating the interpretation of safety signals.
-
Aggregate Profile: Vector aggregates can alter biodistribution patterns and elicit non-specific inflammatory responses in NHP models, masking the true safety profile of the monomeric vector.
-
Process-Related Impurities: Residual host cell proteins, DNA, or purification reagents must be minimized to levels that do not interfere with the toxicological assessment.
Aligning Vector Production with Preclinical Endpoints
A standardized manufacturing template does not exist for next-generation therapies. The production strategy must be tailored to the specific modality and target indication. For instance, the selection of AAV9 or AAVrh10 capsids for central nervous system targets requires a process that accounts for the intended route of administration, such as intrathecal injection, which has been shown to be more effective for CNS delivery than intravenous routes (PMID: 26447927). This alignment ensures that the vector’s performance in NHP models is predictive of its behavior in clinical settings.
This tailored approach is exemplified by a recent program, initiated in 2023 with our core scientific team prior to the formal launch of Franklin Biolabs. The AAV vector manufactured through this collaboration established the foundation for a partner’s gene therapy candidate, now advancing to IND-enabling studies. The seamless transition of this program demonstrates our capacity for providing uninterrupted scientific partnership and long-term project continuity.
Manufacturing for In Vivo Readiness
A robust preclinical program requires confidence that the therapeutic vector is manufactured to specifications appropriate for in vivo administration in large animal models. Our processes are designed to produce material with the purity and characterization profile needed for formal toxicology and biodistribution programs.
This work is executed within our >100,000 sq ft facility, enabling programs to move from candidate selection to IND submission within an 18-24 month timeline. By focusing on a manufacturing process that anticipates regulatory scrutiny from the outset, we help minimize variables that could confound NHP study outcomes.
This service is a component of our broader AAV capabilities. For more information on our discovery-phase support, please see our main AAV Research Vector Packaging Services page.
This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.